FDA’s prime drug regulator, George Tidmarsh, resigns amid probe
WASHINGTON — George Tidmarsh, the Meals and Drug Administration’s prime regulator of medicine, has resigned after being accused of utilizing his regulatory authority to inflict monetary hurt on a former enterprise affiliate, STAT has discovered.
FDA Commissioner Marty Makary positioned Tidmarsh on administrative depart after opening an investigation into his conduct in current days based mostly on a grievance filed towards Tidmarsh by Kevin Tang, a San Diego-based well being care investor and enterprise proprietor. One among Tang’s affiliated firms, Aurinia Prescribed drugs, filed a lawsuit towards Tidmarsh on Sunday, accusing him of a “longstanding private vendetta towards Kevin Tang.”
In an interview with STAT, Tidmarsh confirmed he was positioned on depart from his position because the director of the FDA’s Middle for Drug Analysis and Analysis. Makary knowledgeable him about Tang’s grievance on Friday, however Tidmarsh didn’t discover out he had been positioned on depart till he was locked out of his company e mail account on Saturday. Tidmarsh denies any wrongdoing.
In an announcement, a spokesperson for the Division of Well being and Human Companies, which oversees the FDA, mentioned Tidmarsh resigned Sunday morning “efficient instantly.”
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
